NAS:CHEK (Israel)
Business Description
Check-Cap Ltd
29 Abba Hushi Avenue, Check-Cap Building, P.O. Box 1271, Isfiya, ISR, 3009000
Description
Check-Cap Ltd is a clinical-stage medical diagnostics company engaged in the development of an ingestible imaging capsule that utilizes low-dose X-rays for the detection and imaging of colonic polyps and colorectal cancers, or CRC. The company is developing C-Scan, the first capsule-based system for preparation-free, colorectal cancer screening. Its scanning capsule will be swallowed and propelled by natural motility through the gastrointestinal tract and excreted naturally with no need for retrieval for data collection.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 47.34 | |||||
| Equity-to-Asset | 0.91 | |||||
| Debt-to-Equity | 0.02 | |||||
| Debt-to-EBITDA | -0.06 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 4/9 | |||||
| Altman Z-Score | 0 | |||||
| Beneish M-Score | 0 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 57 | |||||
| 3-Year EPS without NRI Growth Rate | 56.8 | |||||
| 3-Year FCF Growth Rate | 56.4 | |||||
| 3-Year Book Growth Rate | -40.1 |
Momentum Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 65.83 | |||||
| 9-Day RSI | 62.37 | |||||
| 14-Day RSI | 58.68 | |||||
| 6-1 Month Momentum % | -44.9 | |||||
| 12-1 Month Momentum % | -65.53 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 12.05 | |||||
| Quick Ratio | 12.05 | |||||
| Cash Ratio | 11.79 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -162.5 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -44.06 | |||||
| ROA % | -39.74 | |||||
| ROIC % | -413.89 | |||||
| ROC (Joel Greenblatt) % | -761.25 | |||||
| ROCE % | -43.21 | |||||
| Years of Profitability over Past 10-Year | 1 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 0.8 | |||||
| Price-to-Tangible-Book | 0.78 | |||||
| EV-to-EBIT | 0.57 | |||||
| EV-to-EBITDA | 0.57 | |||||
| EV-to-FCF | 0.64 | |||||
| Price-to-Net-Current-Asset-Value | 0.82 | |||||
| Price-to-Net-Cash | 0.83 | |||||
| Earnings Yield (Greenblatt) % | 176.16 |
Guru Trades
See DetailsEMBED
SAVE
Insider Trades
See DetailsEMBED
SAVE
Gurus Latest Trades with NAS:CHEK
Executives
EMBED
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 0 | ||
| EPS (TTM) ($) | -0.22 | ||
| Beta | -0.22 | ||
| Volatility % | 42.76 | ||
| 14-Day RSI | 58.68 | ||
| 14-Day ATR ($) | 0.025293 | ||
| 20-Day SMA ($) | 0.336905 | ||
| 12-1 Month Momentum % | -65.53 | ||
| 52-Week Range ($) | 0.29 - 1.31 | ||
| Shares Outstanding (Mil) | 116.41 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Check-Cap Ltd Filings
| Document | Form | Filing Date | ||
|---|---|---|---|---|
| No Filing Data | ||||